[Dutch Medicines Act also applicable to repurposing]

Area of Science:

• Medical Law
• Pharmacology
• Drug Regulation

Background:

• Article 68 of the Dutch Medicines Act governs off-label drug prescriptions.
• On-label medications are authorized with proven efficacy and safety.
• Repurposed drugs may be prescribed off-label under specific conditions.

Purpose of the Study:

• To evaluate the implications of a more liberal application of Article 68 for repurposed drugs.
• To assess the potential risks associated with off-label prescribing of inadequately substantiated medications.

Main Methods:

• Literature review and legal analysis of Article 68.
• Discussion of the evidence requirements for drug authorization and off-label use.
• Argumentative analysis of the proposed liberal interpretation.

Main Results:

• A more liberal application of Article 68 could permit prescribing drugs without sufficient evidence of efficacy and safety.
• This approach poses unwarranted risks for patients, irrespective of whether the drug is repurposed or not.
• Existing regulatory frameworks ensure benefit-risk assessment for authorized medicines.

Conclusions:

• The current restrictions under Article 68 are essential for safeguarding public health.
• A liberalized approach to off-label prescribing of repurposed drugs is unwarranted and potentially dangerous.
• Maintaining rigorous evidence standards for all drug prescriptions is paramount.